Efficacy and Safety of ELIXCYTE Intra-articular Injection in Subject With Knee Osteoarthritis

PHASE3RecruitingINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

July 3, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Knee Osteoarthritis
Interventions
BIOLOGICAL

ELIXCYTE

ELIXCYTE, a new investigational product developed by UnicoCell Biomed, contains allogenic Adipose-derived stem cells (ADSCs). The ADSCs of ELIXCYTE for subjects were obtained from donors, and the Sponsor followed the manufacturing and testing procedures described in chemistry, manufacturing and control (CMC) information in order to assure the quality of final products.

DRUG

Saline

Placebo control used in the study.

Trial Locations (4)

112

RECRUITING

Taipei Veterans General Hospital, Taipei

333

RECRUITING

Chang Gung Memorial Hospital, Linkou, Taoyuan District

23561

RECRUITING

Taipei Medical University Shuang-Ho Hospital, New Taipei City

Unknown

RECRUITING

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

UnicoCell Biomed CO. LTD

INDUSTRY